📣 Artialis is pleased to announce the end of recruitment of its first clinical study on COVID-19 (CHOPIN with Nasafytol). In this comparative randomized clinical trial, patients received NASAFYTOL (curcumin and quercetin) as a nutritional support to the standard treatment of hospitalized patients infected with COVID-19.
➡ More information on ClinicalTrials.gov
Identifier : NCT04844658
We thank the Sponsor for its trust toward Artialis’ services.
Artialis, a leader CRO located in Belgium has demonstrated that it can ensure fast recruitment in infectious disease.